Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft
- Status
- WITHDRAWN
- Phase
- PHASE2
Clinical Trials Related to Multiple Myeloma
Related studies linked through entity extraction aliases.
Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT
- Status
- UNKNOWN
- Phase
- PHASE2/PHASE3
CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig
- Status
- COMPLETED
- Phase
- PHASE1
A Safety Study of SGN-CD48A in Patients With Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
Ixazomib Plus Lenalidomide Plus Dexamethasone for Newly Diagnosed Myeloma Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission
- Status
- TERMINATED
- Phase
- PHASE2
Long-term Follow-up Study of Patients Receiving CAR-T Cells
- Status
- RECRUITING
- Phase
- N/A
Global Response Assessment by Advanced Imaging and Myeloma Lesion Biopsies During Induction Therapy of Multiple Myeloma With Carfilzomib Lenalidomide Dexamethasone
- Status
- COMPLETED
- Phase
- NA
A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Prevalence, Intensity and Consequences of Bortezomib-induced Neuropathic Disorders.
- Status
- COMPLETED
- Phase
- N/A
Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma
- Status
- UNKNOWN
- Phase
- PHASE2
Use of Zarzio® in Post-autologous Stem Cell Transplantation Procedure
- Status
- COMPLETED
- Phase
- N/A
Study of BCMA CAR-T in Multiple Myeloma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Identification of Occupational Exposures in Acute Hematologic Malignancy
- Status
- COMPLETED
- Phase
- N/A
Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
- Status
- RECRUITING
- Phase
- PHASE2